A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
Completed · Phase 2 · Has a placebo group
Conditions studied: Alzheimer Disease, Dementia of Alzheimer Type
In brief
This study is designed to evaluate treatment effects of ATH-1017 (fosgonimeton) in mild to moderate Alzheimer's subjects with a randomized treatment duration of 26-weeks.
Key facts
- Study ID
- NCT04491006
- Run by
- LeonaBio
- People needed
- 77
- Starts
- 2020-11-23
- Expected to finish
- 2022-05-20
- Last updated by the study team
- 2023-06-12
Who can join
Age: 55 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Syrentis Clinical Research — Santa Ana, California, United States
- Premiere Research Institute — West Palm Beach, Florida, United States
- iResearch Atlanta — Decatur, Georgia, United States
- Neurological Associates of Albany — Albany, New York, United States
- Center for Cognitive Health — Portland, Oregon, United States
- Evergreen Health Research Program — Kirkland, Washington, United States
- University of Washington — Seattle, Washington, United States
- Central Coast Neurosciences Research — Central Coast, New South Wales, Australia
- St Vincent's Centre for Applied Medical Research, Translational Research Centre — Darlinghurst, New South Wales, Australia
- Hammondcare Greenwich Hospital — Greenwich, New South Wales, Australia
- KaRa MINDS — Macquarie Park, New South Wales, Australia
- HammondCare — Malvern, Victoria, Australia
- Australian Alzheimer's Research Organization — Nedlands, Western Australia, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.